Abstract
Staphylococcus epidermidis is a major cause of periprosthetic joint infection (PJI); its intracellular persistence within osteoblasts may compromise therapy if that therapy is not intracellularly active. The intracellular activity of rifampin, rifapentine, and rifabutin was assessed against five rifampin-susceptible and two rifampin-resistant S. epidermidis isolates. Compared to no treatment, treatment resulted in a ≥2-fold log10 reduction of intracellular rifampin-susceptible, but not rifampin-resistant, S. epidermidis These findings show activity of rifampin, rifapentine, and rifabutin against intraosteoblast PJI-associated S. epidermidis.
References
May 1, 1992·Infection and Immunity·D MackR Laufs
Nov 28, 2006·Best Practice & Research. Clinical Rheumatology·Werner Zimmerli
Mar 20, 2010·Tuberculosis·Paul A AristoffH D Showalter
Dec 12, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Douglas R OsmonUNKNOWN Infectious Diseases Society of America
Jul 11, 2013·PloS One·Florent ValourUNKNOWN Lyon BJI Study Group
Apr 4, 2014·Clinical Microbiology Reviews·Aaron J Tande, Robin Patel
Oct 24, 2014·European Cells & Materials·W MohamedV Alt
Apr 22, 2015·Clinical Orthopaedics and Related Research·Carlos J SanchezJoseph C Wenke
Dec 31, 2017·International Journal of Antimicrobial Agents·Yu Mi WiRobin Patel
Aug 1, 2018·Infection and Immunity·Kimberly Perez, Robin Patel
Aug 28, 2019·Antimicrobial Agents and Chemotherapy·Mariana AlbanoRobin Patel
Mar 3, 2020·Journal of Bone and Joint Infection·A BeckerT Ferry
Mar 4, 2020·The Journal of Antimicrobial Chemotherapy·Lélia AbadFlorent Valour
Sep 12, 2020·The Journal of Infectious Diseases·Melissa J KarauRobin Patel